Clinical trials: HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression

HER2-mutated Advanced Non-small Cell Lung Cancer With Oligoprogression

A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer

• Not yet recruiting
• Age: 18 to 75 years
• Phase 2

A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined with Radiotherapy in Patients with HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer

Trial name

NCT07781202

Testing

Trastuzumab Rezetecan combined with radiotherapy

Volunteers

30 people

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology